Anixa Biosciences (ANIX) Projected to Post Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX) is projected to issue its quarterly earnings data before the market opens on Tuesday, January 21st. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $2.41 on Friday. The firm has a market capitalization of $77.55 million, a price-to-earnings ratio of -6.18 and a beta of 0.90. Anixa Biosciences has a 52-week low of $2.07 and a 52-week high of $5.13. The stock has a fifty day moving average of $2.80 and a 200 day moving average of $3.03.

Insider Buying and Selling

In related news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the firm’s stock in a transaction on Friday, January 17th. The shares were bought at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the acquisition, the director now directly owns 922,334 shares in the company, valued at $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Amit Kumar bought 43,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was bought at an average cost of $2.23 per share, with a total value of $95,890.00. Following the transaction, the chief executive officer now directly owns 559,925 shares in the company, valued at approximately $1,248,632.75. The trade was a 8.32 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 62,289 shares of company stock valued at $141,561 over the last 90 days. Insiders own 22.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ANIX. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, January 14th. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.